Cargando…

P1293: COMBINING THE IAP ANTAGONIST, TOLINAPANT, WITH A DNA HYPOMETHYLATING AGENT ENHANCES ANTI-TUMOUR MECHANISMS IN PRECLINICAL MODELS OF T-CELL LYMPHOMA.

Detalles Bibliográficos
Autores principales:	Sims, M., Ward, G., Zhang, Z., Jueliger, S., Davis, M., Boxall, A., Taylor, J., Biondo, A., Lyons, J., Smyth, T.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2022
Materias:	Posters
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9429225/ http://dx.doi.org/10.1097/01.HS9.0000848036.19417.16

Ejemplares similares

P1278: ACTIVATION OF THE NECROPTOSIS PATHWAY PLAYS A ROLE IN SYNERGISM WITH COMBINATION OF THE IAP ANTAGONIST, TOLINAPANT AND HYPOMETHYLATING AGENTS (HMA) IN IN VITRO MODELS OF T-CELL LYMPHOMA (TCL).
por: Manavalan, J. S., et al.
Publicado: (2022)

Clinical Positioning of the IAP Antagonist Tolinapant (ASTX660) in Colorectal Cancer
por: Crawford, Nyree, et al.
Publicado: (2021)

Efficacy and epigenetic interactions of novel DNA hypomethylating agent guadecitabine (SGI-110) in preclinical models of hepatocellular carcinoma
por: Jueliger, Simone, et al.
Publicado: (2016)

Antagonism of inhibitors of apoptosis proteins reveals a novel, immune response-based therapeutic approach for T-cell lymphoma
por: Ferrari, Nicola, et al.
Publicado: (2021)

Locus-specific hypomethylation of the mouse IAP retrotransposon is associated with transcription factor-binding sites
por: Shimosuga, Ken-ichi, et al.
Publicado: (2017)

Bivalent IAP antagonists, but not monovalent IAP antagonists, inhibit TNF-mediated NF-κB signaling by degrading TRAF2-associated cIAP1 in cancer cells
por: Mitsuuchi, Y, et al.
Publicado: (2017)

1293 Clinical Characteristics of Botulism in the United States, 2002–2012
por: Rao, Agam K., et al.
Publicado: (2014)

Triggering necroptosis in cisplatin and IAP antagonist-resistant ovarian carcinoma
por: McCabe, K E, et al.
Publicado: (2014)

Lipopolysaccharide sensitizes the therapeutic response of breast cancer to IAP antagonist
por: Liu, Xin, et al.
Publicado: (2022)

The expanding role of IAP antagonists for the treatment of head and neck cancer
por: Kansal, Vikash, et al.
Publicado: (2023)

Bivalent IAP antagonists inhibit TRAF2-bound cIAPs and limit TNF-mediated NF-κB signaling
por: Condon, Stephen M
Publicado: (2016)

Drosophila IAP antagonists form multimeric complexes to promote cell death
por: Sandu, Cristinel, et al.
Publicado: (2010)

IAP antagonists sensitize murine osteosarcoma cells to killing by TNFα
por: Shekhar, Tanmay M., et al.
Publicado: (2016)

The IAP antagonist birinapant potentiates bortezomib anti-myeloma activity in vitro and in vivo
por: Zhou, Liang, et al.
Publicado: (2019)

1293P Impact of COVID epidemy on palliative care referrals in a national cancer center
por: Ebert Moltara, M., et al.
Publicado: (2022)

IAP antagonist GDC-0917 is more potent than Debio1143 in promoting cell death, c-IAP1 degradation and tumor growth inhibition
por: Alicke, Bruno, et al.
Publicado: (2022)

PTEN deficiency promotes macrophage infiltration and hypersensitivity of prostate cancer to IAP antagonist/radiation combination therapy
por: Armstrong, Chris W.D., et al.
Publicado: (2016)

IAP Workshop
Publicado: (1996)

miR-1293 acts as a tumor promotor in lung adenocarcinoma via targeting phosphoglucomutase 5
por: Chen, Bing, et al.
Publicado: (2021)

TRAF2/3 deficient B cells resist DNA damage-induced apoptosis via NF-κB2/XIAP/cIAP2 axis and IAP antagonist sensitizes mutant lymphomas to chemotherapeutic drugs
por: Vashisht, Monika, et al.
Publicado: (2023)

Examining the In Vitro Efficacy of the IAP Antagonist Birinapant as a Single Agent or in Combination With Dacarbazine to Induce Melanoma Cell Death
por: Vetma, Vesna, et al.
Publicado: (2017)

Effects of Physiological and Synthetic IAP Antagonism on c-IAP-Dependent Signaling
por: Kocab, Andrew J., et al.
Publicado: (2015)

Taking aim with IAP antagonists at triple-negative breast cancer: a moving target no more?
por: LaCasse, Eric C.
Publicado: (2020)

The non‐peptidomimetic IAP antagonist ASTX660 sensitizes colorectal cancer cells for extrinsic apoptosis
por: Knoll, Gertrud, et al.
Publicado: (2021)

Characterization of a Potent and Orally Bioavailable Lys-Covalent Inhibitor of Apoptosis Protein (IAP) Antagonist
por: Udompholkul, Parima, et al.
Publicado: (2023)

A Large Dominant Myotonia Congenita Family with a V1293I Mutation in SCN4A
por: Chung, Ki Wha, et al.
Publicado: (2016)

Short superficial white matter and aging: A longitudinal multi-site study of 1293 subjects and 2711 sessions
por: Schilling, Kurt G., et al.
Publicado: (2023)

Pre-Clinical Evaluation of the Hypomethylating Agent Decitabine for the Treatment of T-Cell Lymphoblastic Lymphoma
por: Provez, Lien, et al.
Publicado: (2023)

IAP antagonists Birinapant and AT-406 efficiently synergise with either TRAIL, BRAF, or BCL-2 inhibitors to sensitise BRAFV600E colorectal tumour cells to apoptosis
por: Perimenis, Philippos, et al.
Publicado: (2016)

IAP textbook of vaccines
por: Kabra, S. K.
Publicado: (2016)

IAPS Presidential Address
por: Ramadwar, Ravindra
Publicado: (2022)

IAP-IAP Complexes Required for Apoptosis Resistance of C. trachomatis–Infected Cells
por: Rajalingam, Krishnaraj, et al.
Publicado: (2006)

1293. Bundled HIV/Hep C testing 4 Years of Implementation at 9 Emergency Departments in the Houston Metropolitan Area
por: Rodriguez, Gilhen, et al.
Publicado: (2019)

Identification of mTOR as a primary resistance factor of the IAP antagonist AT406 in hepatocellular carcinoma cells
por: Zhen, Mao-Chuan, et al.
Publicado: (2016)

Structure-based design, synthesis, and evaluation of the biological activity of novel phosphoroorganic small molecule IAP antagonists
por: Łupicka-Słowik, Agnieszka, et al.
Publicado: (2020)

The IAP Antagonist SM-164 Eliminates Triple-Negative Breast Cancer Metastasis to Bone and Lung in Mice
por: Lei, Wei, et al.
Publicado: (2020)

The IAP antagonist birinapant enhances chimeric antigen receptor T cell therapy for glioblastoma by overcoming antigen heterogeneity
por: Song, Edward Z., et al.
Publicado: (2022)

Hypomethylation coordinates antagonistically with hypermethylation in cancer development: a case study of leukemia
por: Kushwaha, Garima, et al.
Publicado: (2016)

The preclinical efficacy of the novel hypomethylating agent NTX-301 as a monotherapy and in combination with venetoclax in acute myeloid leukemia
por: Lim, Byungho, et al.
Publicado: (2022)

IAP Display: A Simple Method to Identify Mouse Strain Specific IAP Insertions
por: Ray, Akshay, et al.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_eemgihmulqrkio2scf916ul8ft